The specificity of the binding of platelet activating factor (PAF) to anti-PAF antibodies.
Quantitative hapten inhibition experiments employing sheep anti-PAF antibodies and selected PAF analogues were undertaken with the aim of defining the antigenic determinant structures complementary to the antibody combining sites. The most important fine structural features for inhibition of antibody to PAF were shown to be an acetyl group at position 2 of the phospholipid glycerol backbone and an ether group at position 1. Of the naturally occurring compounds, C16- and C18:1-PAF proved to be the most potent inhibitors and more active than C18-PAF while phospholipids with a propionyl, butyryl or hexanoyl group at position 2 showed either weak or no inhibitory activity. The 1-acyl, thioether and deoxy analogues proved inactive. Variations in the polar head group of PAF were found to be less critical with, for example, the dimethyl and ethanolamine derivatives retaining some activity. This antibody recognition pattern is very similar to that of the PAF receptor, although the antibodies appear to have a more specific requirement for an acyl linkage at position 2.
Smal
M A
MA
Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, NSW, Australia.
Baldo
B A
BA
Harle
D G
DG
D000818:Animals; D000906:Antibodies / Q000276:immunology*; D000918:Antibody Specificity; D000939:Epitopes; D006241:Haptens; D008958:Models, Molecular; D010972:Platelet Activating Factor / Q000276:immunology* / Q000378:metabolism; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled; D012756:Sheep; D013379:Substrate Specificity
D000906:Antibodies; D000939:Epitopes; D006241:Haptens; D010972:Platelet Activating Factor; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; C039351:platelet activating factor receptor